Neural Regeneration Research ›› 2021, Vol. 16 ›› Issue (9): 1772-1773.doi: 10.4103/1673-5374.306086

Previous Articles     Next Articles

Preventative medicine and Alzheimer’s disease: is Alzheimer’s disease risk reduction achievable?

Benjamin Sinyor*, Richard Isaacson, Christopher Ochner   

  1. HCA Healthcare, Nashville, TN, USA (Sinyor B, Ochner C)
    Weil Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA (Isaacson R)
  • Online:2021-09-15 Published:2021-02-05
  • Contact: Benjamin Sinyor, MD, MPH, benjamin.sinyor@hcahlealthcare.com.
  • Supported by:
    HCA Healthcare supported this work (in whole or in part) and/or an HCA Healthcare affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities. 

Abstract: Alzheimer’s disease (AD) has a multifactorial etiology that has eluded scientists and clinicians for decades. This incomplete understanding of the causal factors likely contributes to the dearth of effective therapeutics available to treat this growing pandemic. Cholinesterase inhibitors such as galantamine, rivastigmine and donepezil are considered frontline treatments but these medications merely treat some of the symptoms associated with AD, rather than curing or even slowing the progression of the disease. This has caused some investigators and clinicians to start exploring the potential to prevent AD. However, the concept of AD has gained widespread acceptance in the clinical community, with many stating that the prevention of AD is impossible. While we would concede that reducing the likelihood of AD development to zero is impossible, these authors argue that significant reduction of the risk of developing AD, particularly in patients at an elevated risk for AD development, is achievable today, and can save many lives and life years.